MedTrace Logo

Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection

NCT04361903 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2020-04-24

No results posted yet for this study

Summary

It is an observational, cohort, retrospective, monocentric, non-profit study. The primary objective is to evaluate the efficacy and safety of ruxolitinib in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19 with rapid deterioration of respiratory parameters in the last 12 hours.

Conditions

  • Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

DRUG

Ruxolitinib Oral Tablet

Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours

Sponsors & Collaborators

  • Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy

    collaborator OTHER_GOV

  • Azienda Ospedaliera Universitaria Senese

    collaborator OTHER

  • Azienda Ospedaliero, Universitaria Pisana

    collaborator OTHER

  • Azienda USL Toscana Nord Ovest

    lead OTHER

Principal Investigators

  • Enrico Dr Capochiani, hematologist · Azienda USL Toscana Nord Ovest

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-25
Primary Completion
2020-05-24
Completion
2020-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04361903 on ClinicalTrials.gov